CorMedix (CRMD)
Sells an FDA-approved catheter lock solution and a portfolio of hospital anti-infective drugs across the US.
Something off on this page? Send us feedback.
Sells DefenCath, an antimicrobial catheter lock solution for dialysis patients, alongside a broader portfolio of hospital anti-infective drugs added through an acquisition, generating revenue primarily from US hospitals and outpatient dialysis providers.
Develops and commercializes anti-infective therapies for hospital and dialysis settings, anchored by DefenCath, an antimicrobial catheter lock solution that prevents bloodstream infections in patients on chronic hemodialysis through a central venous catheter — the first FDA-approved product of its kind in the US.
A subsequent acquisition of Melinta Therapeutics added a portfolio of marketed antibiotics for hospital-acquired infections, broadening the business beyond a single product into a diversified anti-infective franchise sold primarily to US hospitals and dialysis providers.
Originally organized around cardiorenal disease research, the company pivoted to the US anti-infective market after winding down its European operations, and DefenCath itself reached the market only after two manufacturing-related regulatory rejections delayed its approval by several years. Commercial performance depends on hospital and dialysis-center adoption, third-party manufacturing quality, and Medicare reimbursement mechanisms for outpatient dialysis use.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Initiate | Rating: —Target: — | Target: $15 |
| Apr 28, 2026 | RBC Capital | Reiterate | Rating: —Target: $13 | Target: $14 |
| Mar 6, 2026 | Leerink Partners | Target | Target: — | Target: $13 |
| Jan 23, 2026 | H.C. Wainwright | Target | Target: $17 | Target: $13 |
| Jan 21, 2026 | RBC Capital | Reiterate | Rating: —Target: $22 | Target: $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $256.7M · Total debt $145.2M · Total assets $904.1M · Shareholders' equity $460.8M
- Revenue
- $101.9M
- Operating income
- $42.9M
- Net income
- $26.0M
No dividends on record.
| Institutions | 57.26% | 44.63M shares | |
|---|---|---|---|
| 205 holders · as of Jun 30, 2026 | |||
| Insiders | 9.06% | 7.06M shares | |
| 14 holders · as of Sep 18, 2026 | |||
| Other | 33.68% | 26.25M shares | |
| remainder | |||
77.94M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.11% | 6.32M | as of Jun 30, 2026 |
Deep Track Capital, LPInstitution | 8.05% | 6.27M | as of Jun 30, 2026 |
Shaibatalhamd Aymen AbdalkaderInsider | 5.93% | 4.62M | filed Jun 12, 2026 |
Vanguard Capital Management LLCInstitution | 4.02% | 3.14M | as of Jun 30, 2026 |
State Street CorpInstitution | 2.97% | 2.32M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 21, 2026 | Janet Dillione | director | −10,000 | $6.88 |
| Dec 30, 2025 | Alan W. Dunton | director | −20,000 | $13.00 |
| Dec 18, 2025 | Joseph Todisco | director, officer: Chief Executive Officer | −30,000 | $12.00 |
| Dec 9, 2025 | Janet Dillione | director | −34,000 | $12.00 |
| Dec 9, 2025 | Steven W. Lefkowitz | director | −40,000 | $11.88 |
- Innoviva
Head-to-head in resistant Gram-negative hospital infections and HABP/VABP
- Merck
Head-to-head in carbapenem + beta-lactamase-inhibitor Gram-negative antibiotics
- AbbVie
Head-to-head in resistant Gram-negative hospital infections via Avycaz
- Gilead Sciences
Head-to-head in invasive fungal infections via AmBisome
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| CorMedix | $7.64 | −1.86% | $610.4M | 3.7 | — | 1.3 | +156.5% |
| Innoviva | $20.56 | −2.00% | $1.55B | 5.1 | 9.6 | 3.5 | +19.3% |
| Merck | $147.52 | −2.25% | $372.73B | 120.7 | 17.1 | 5.6 | +5.1% |
| AbbVie | $264.72 | −0.18% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Gilead Sciences | $150.45 | −1.46% | $189.30B | — | 16.6 | 6.2 | +10.2% |
| Median | 74.8 | 16.9 | 5.9 | +10.2% |